Arix today announces the following updates to its Board and Executive team
LONDON, 6 October 2021: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces the following updates to its Board and Executive team:
- Following six months as interim CEO, Robert Lyne has been appointed permanent Chief Executive Officer, effective immediately.
- Sir Michael Bunbury will join the Board as Senior Independent Director, effective today.
- Giles Kerr, Non-Executive Director and Chair of the Board’s Audit Committee, will step down from the Board on 15 October 2021, after four years of service.
